BullishAgent BullishAgent SEC Filings Earnings Calendar Analyst Ratings IPOs Insiders Institutional Funds Screener
Sign in Register

DHR

Danaher Corporation NYSE
Healthcare ·Medical - Diagnostics & Research ·US · danaher.com
$175.15
After hrs $174.04 +0.00%
Mkt Cap $124.5B
52w Low $175.00 0.2% of range 52w High $242.80
50d MA $194.30 200d MA $208.86
P/E (TTM) 34.5x
EV/EBITDA 25.3x
P/B 2.4x
Debt/Equity 0.3x
ROE 7.0%
P/FCF 30.8x
RSI (14)
ATR (14)
Beta 0.99
50d MA $194.30
200d MA $208.86
Avg Volume 4.4M
About
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterizatio…
Recent Earnings
Date Time Est Rptd Surp Base Gap% D1% D2% D3% D4% D5% 1M% Guide ▲★
Apr 21, 2026 AMC 1.94 2.06 +6.2% 194.54 -0.3% -5.4% -8.2% -8.9% -7.2% -8.0%
Jan 28, 2026 AMC 2.16 2.23 +3.2% 224.54 -0.5% -2.2% -2.5% -0.5% -3.5% -2.2% -6.2%
Oct 21, 2025 AMC 1.72 1.89 +9.9% 220.77 +0.8% -1.2% +0.9% +1.0% +0.1% -1.8% +0.6%
Jul 22, 2025 AMC 1.64 1.80 +9.8% 189.91 +5.6% +4.2% +6.8% +8.2% +6.9% +8.9% +7.4%
Apr 22, 2025 AMC 1.63 1.88 +15.3% 192.07 +4.1% +2.2% +2.3% +2.6% +2.0% +3.6% -2.4%
Jan 29, 2025 AMC 2.14 2.14 +0.0% 223.73 +0.6% -0.3% -0.4% -4.2% -3.9% -5.2% -7.1%
Oct 22, 2024 AMC 1.57 1.71 +8.9% 261.28 -1.1% -2.0% -5.1% -6.1% -6.6% -7.1% -10.0%
Jul 23, 2024 AMC 1.57 1.72 +9.6% 264.18 -0.9% +0.6% +2.2% +3.7% +2.8% +4.2% +1.4%
Apr 23, 2024 AMC 1.72 1.92 +11.6% 253.11 -1.6% -1.1% -2.9% -2.6% -2.5% -2.6% +3.3%
Jan 30, 2024 AMC 1.90 2.09 +10.0% 244.95 +0.3% -2.1% +0.1% +0.6% +0.4% +1.3% +3.3%
Recent Analyst Ratings
Date Firm Action Grade Target Base Open Gap% D1% D2% D3% D4% D5%
Apr 23 Morgan Stanley Maintains Overweight → Overweight $184.04 $180.82 -1.7% -3.0% -3.7% -1.9% -2.7% -2.8%
Apr 22 Wells Fargo Maintains Equal Weight → Equal Weight $194.54 $193.95 -0.3% -5.4% -8.2% -8.9% -7.2% -8.0%
Apr 22 Baird Maintains Outperform → Outperform $194.54 $193.95 -0.3% -5.4% -8.2% -8.9% -7.2% -8.0%
Apr 22 Guggenheim Maintains Buy → Buy $194.54 $193.95 -0.3% -5.4% -8.2% -8.9% -7.2% -8.0%
Apr 22 UBS Maintains Buy → Buy $194.54 $193.95 -0.3% -5.4% -8.2% -8.9% -7.2% -8.0%
Apr 17 Baird Maintains Outperform → Outperform $193.78 $194.58 +0.4% +0.5% +0.9% +0.4% -5.0% -7.8%
Apr 14 Barclays Maintains Overweight → Overweight $195.87 $195.62 -0.1% +1.4% +1.2% -1.1% -0.6% -0.2%
Apr 13 Goldman Sachs Maintains Buy → Buy $189.61 $188.67 -0.5% +3.3% +4.7% +4.5% +2.2% +2.7%
Apr 6 Evercore ISI Maintains Outperform → Outperform $191.12 $190.63 -0.3% +0.5% -0.1% +2.7% +1.0% -0.8%
Jan 29 JP Morgan Maintains Overweight → Overweight $224.54 $223.32 -0.5% -2.2% -2.5% -0.5% -3.5% -2.2%
Recent Filings
8-K · 7.01 ! Medium
Masimo Corporation -- 8-K 7.01: Regulation FD Disclosure
Masimo disclosed material information via press release that investors should review in Exhibit 99.1 for details on developments affecting the company and its parent Danaher.
May 4
8-K
Masimo Corporation -- 8-K Filing
Masimo faces three stockholder lawsuits challenging its merger with Danaher, filed after the definitive proxy statement was disclosed, potentially delaying or jeopardizing the transaction's completion.
Apr 23
8-K
Danaher Corporation -- 8-K Filing
Danaher reported Q1 2026 results from continuing operations, with year-over-year comparisons providing investors insight into the conglomerate's operational performance across its diversified portfolio.
Apr 21
— 8-K filing (BAC, BNPQF, DHR)
Apr 17
8-K · 1.01 ! Medium
Danaher Corporation -- 8-K 1.01: Financing / Debt Agreement
Danaher secured a credit facility extending to April 2027 with a one-year extension option available upon 0.50% fee payment, providing financial flexibility for capital management.
Apr 17
8-K · 5.02 !!! Very High
Unknown — 8-K 5.02: Executive Change
An experienced life sciences executive is joining one of these companies, likely signaling leadership transition or strategic expansion in biotech/pharma sectors, which could impact growth direction and investor confidence.
Apr 7
8-K · 5.02 !!! Very High
Danaher Corporation -- 8-K 5.02: Executive Change
Danaher's appointment of a new executive signals potential strategic shifts in operations and governance; investors should monitor announcements regarding leadership responsibilities and company direction.
Feb 17
8-K
Danaher Corporation -- 8-K Filing
Danaher's 8-K disclosure likely addresses a material event—possibly an acquisition, dividend change, or executive transition—that could significantly impact earnings, cash flow, or strategic direction, warranting investor review.
Feb 10
Data updated apr 25, 2026 5:10am · Source: massive.com